Controlling toxicity of Peptide-drug conjugates by different chemical linker structures.

about

Neuropeptide Y receptors: a promising target for cancer imaging and therapy.Peptides@mica: from affinity to adhesion mechanism.

P2860

Q38713678-93B3A6F8-D557-454C-A0DB-07E89C51E9F8 Q39524265-F2E3C4D0-37D1-47AB-BB65-D7922C25E9FB

P2860

Controlling toxicity of Peptide-drug conjugates by different chemical linker structures.

Item

http://www.wikidata.org/entity/Q38882129

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Controlling toxicity of Peptide-drug conjugates by different chemical linker structures.

@en

type

Item

label

Controlling toxicity of Peptide-drug conjugates by different chemical linker structures.

@en

prefLabel

Controlling toxicity of Peptide-drug conjugates by different chemical linker structures.

@en

P1476

Controlling toxicity of Peptide-drug conjugates by different chemical linker structures.

@en

P2093

Annette G Beck-Sickinger

http://www.w3.org/2001/XMLSchema#string

David Böhme

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY

Automated solid-phase peptide synthesis to obtain therapeutic peptides

Novel peptide conjugates for tumor-specific chemotherapy.

The GRAFS classification system of G-protein coupled receptors in comparative perspective.

Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience.

Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases.

Mechanisms of action of methotrexate.

State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines

Combination chemotherapy as an adjuvant treatment in operable breast cancer.

Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5).

P304

804-814

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CMDC.201402514

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25914147

http://www.w3.org/2001/XMLSchema#string

Controlling toxicity of Peptide-drug conjugates by different chemical linker structures.

about

P2860

P2860

Controlling toxicity of Peptide-drug conjugates by different chemical linker structures.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698